Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

During the Trading Day
65.51 -6.80 / -9.40%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
62.60 -2.91 / -4.44%
Volume: 167.9K
Health Technology

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914



Mutual fund holders59.18%
Other institutional36.07%
Individual stakeholders13.92%

Top Executives

Hervé HoppenotChairman, President & Chief Executive Officer
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Richard S. LevyChief Drug Development Officer & Executive VP